Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 198

1.

Predictors of SIV recrudescence following antiretroviral treatment interruption.

Pinkevych M, Fennessey CM, Cromer D, Reid C, Trubey CM, Lifson JD, Keele BF, Davenport MP.

Elife. 2019 Oct 25;8. pii: e49022. doi: 10.7554/eLife.49022. [Epub ahead of print]

2.

In vivo validation of the viral barcoding of SIVmac239 and the development of new barcoded SIV and subtype B and C SHIVs.

Khanal S, Fennessey CM, O'Brien SP, Thorpe A, Reid C, Immonen TT, Smith R, Bess JW Jr, Swanstrom AE, Del Prete GQ, Davenport MP, Okoye AA, Picker LJ, Lifson JD, Keele BF.

J Virol. 2019 Oct 9. pii: JVI.01420-19. doi: 10.1128/JVI.01420-19. [Epub ahead of print]

PMID:
31597757
3.

Defining early SIV replication and dissemination dynamics following vaginal transmission.

Deleage C, Immonen TT, Fennessey CM, Reynaldi A, Reid C, Newman L, Lipkey L, Schlub TE, Camus C, O'Brien S, Smedley J, Conway JM, Del Prete GQ, Davenport MP, Lifson JD, Estes JD, Keele BF.

Sci Adv. 2019 May 29;5(5):eaav7116. doi: 10.1126/sciadv.aav7116. eCollection 2019 May.

4.

Moving the HIV vaccine field forward: concepts of protective immunity.

Kent SJ, Davenport MP.

Lancet HIV. 2019 Jun;6(6):e406-e410. doi: 10.1016/S2352-3018(19)30134-1. Epub 2019 May 9.

PMID:
31080107
5.

The peripheral differentiation of human natural killer T cells.

Liu J, Hill BJ, Darko S, Song K, Quigley MF, Asher TE, Morita Y, Greenaway HY, Venturi V, Douek DC, Davenport MP, Price DA, Roederer M.

Immunol Cell Biol. 2019 Jul;97(6):586-596. doi: 10.1111/imcb.12248. Epub 2019 Apr 8.

6.

Plasmodium-specific antibodies block in vivo parasite growth without clearing infected red blood cells.

Akter J, Khoury DS, Aogo R, Lansink LIM, SheelaNair A, Thomas BS, Laohamonthonkul P, Pernold CPS, Dixon MWA, Soon MSF, Fogg LG, Engel JA, Elliott T, Sebina I, James KR, Cromer D, Davenport MP, Haque A.

PLoS Pathog. 2019 Feb 27;15(2):e1007599. doi: 10.1371/journal.ppat.1007599. eCollection 2019 Feb.

7.

Fate mapping reveals the age structure of the peripheral T cell compartment.

Reynaldi A, Smith NL, Schlub TE, Tabilas C, Venturi V, Rudd BD, Davenport MP.

Proc Natl Acad Sci U S A. 2019 Mar 5;116(10):3974-3981. doi: 10.1073/pnas.1811634116. Epub 2019 Feb 14.

8.

Interaction between maternally derived antibodies and heterogeneity in exposure combined to determine time-to-first Plasmodium falciparum infection in Kenyan infants.

Reynaldi A, Dent AE, Schlub TE, Ogolla S, Rochford R, Davenport MP.

Malar J. 2019 Jan 22;18(1):19. doi: 10.1186/s12936-019-2657-6.

9.

Fc-dependent functions are redundant to efficacy of anti-HIV antibody PGT121 in macaques.

Parsons MS, Lee WS, Kristensen AB, Amarasena T, Khoury G, Wheatley AK, Reynaldi A, Wines BD, Hogarth PM, Davenport MP, Kent SJ.

J Clin Invest. 2019 Jan 2;129(1):182-191. doi: 10.1172/JCI122466. Epub 2018 Nov 26.

10.

Functional cure of HIV: the scale of the challenge.

Davenport MP, Khoury DS, Cromer D, Lewin SR, Kelleher AD, Kent SJ.

Nat Rev Immunol. 2019 Jan;19(1):45-54. doi: 10.1038/s41577-018-0085-4.

PMID:
30410126
11.

In Silico Investigation of the Decline in Clinical Efficacy of Artemisinin Combination Therapies Due to Increasing Artemisinin and Partner Drug Resistance.

Zaloumis SG, Cao P, Dini S, Davenport MP, Cromer D, Khoury DS, Fowkes FJI, McCaw JM, Simpson JA.

Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e01292-18. doi: 10.1128/AAC.01292-18. Print 2018 Dec.

12.

Quantification of host-mediated parasite clearance during blood-stage Plasmodium infection and anti-malarial drug treatment in mice.

Aogo RA, Khoury DS, Cromer D, Elliott T, Akter J, Fogg LG, Nair AS, Liligeto UN, Soon MSF, Thomas BS, Pernold CPS, Romanczuk AS, Laohamonthonkul P, Haque A, Davenport MP.

Int J Parasitol. 2018 Oct;48(12):903-913. doi: 10.1016/j.ijpara.2018.05.010. Epub 2018 Sep 1.

PMID:
30176235
13.

Within-host modeling of blood-stage malaria.

Khoury DS, Aogo R, Randriafanomezantsoa-Radohery G, McCaw JM, Simpson JA, McCarthy JS, Haque A, Cromer D, Davenport MP.

Immunol Rev. 2018 Sep;285(1):168-193. doi: 10.1111/imr.12697. Review.

PMID:
30129195
14.

Lifelong CMV infection improves immune defense in old mice by broadening the mobilized TCR repertoire against third-party infection.

Smithey MJ, Venturi V, Davenport MP, Buntzman AS, Vincent BG, Frelinger JA, Nikolich-Žugich J.

Proc Natl Acad Sci U S A. 2018 Jul 17;115(29):E6817-E6825. doi: 10.1073/pnas.1719451115. Epub 2018 Jul 2.

15.

Developmental Origin Governs CD8+ T Cell Fate Decisions during Infection.

Smith NL, Patel RK, Reynaldi A, Grenier JK, Wang J, Watson NB, Nzingha K, Yee Mon KJ, Peng SA, Grimson A, Davenport MP, Rudd BD.

Cell. 2018 Jun 28;174(1):117-130.e14. doi: 10.1016/j.cell.2018.05.029. Epub 2018 Jun 14.

16.

Molecularly barcoded Zika virus libraries to probe in vivo evolutionary dynamics.

Aliota MT, Dudley DM, Newman CM, Weger-Lucarelli J, Stewart LM, Koenig MR, Breitbach ME, Weiler AM, Semler MR, Barry GL, Zarbock KR, Haj AK, Moriarty RV, Mohns MS, Mohr EL, Venturi V, Schultz-Darken N, Peterson E, Newton W, Schotzko ML, Simmons HA, Mejia A, Hayes JM, Capuano S 3rd, Davenport MP, Friedrich TC, Ebel GD, O'Connor SL, O'Connor DH.

PLoS Pathog. 2018 Mar 28;14(3):e1006964. doi: 10.1371/journal.ppat.1006964. eCollection 2018 Mar.

17.

HIV Reactivation after Partial Protection by Neutralizing Antibodies.

Parsons MS, Cromer D, Davenport MP, Kent SJ.

Trends Immunol. 2018 May;39(5):359-366. doi: 10.1016/j.it.2017.12.006. Epub 2018 Jan 30. Review.

PMID:
29366547
18.

Estimating Initial Viral Levels during Simian Immunodeficiency Virus/Human Immunodeficiency Virus Reactivation from Latency.

Pinkevych M, Fennessey CM, Cromer D, Tolstrup M, Søgaard OS, Rasmussen TA, Keele BF, Davenport MP.

J Virol. 2018 Jan 2;92(2). pii: e01667-17. doi: 10.1128/JVI.01667-17. Print 2018 Jan 15.

19.

Modeling of Antilatency Treatment in HIV: What Is the Optimal Duration of Antiretroviral Therapy-Free HIV Remission?

Cromer D, Pinkevych M, Rasmussen TA, Lewin SR, Kent SJ, Davenport MP.

J Virol. 2017 Nov 30;91(24). pii: e01395-17. doi: 10.1128/JVI.01395-17. Print 2017 Dec 15.

20.

Exploration of broadly neutralizing antibody fragments produced in bacteria for the control of HIV.

Lloyd SB, Niven KP, Kiefel BR, Montefiori DC, Reynaldi A, Davenport MP, Kent SJ, Winnall WR.

Hum Vaccin Immunother. 2017 Nov 2;13(11):2726-2737. doi: 10.1080/21645515.2017.1368935. Epub 2017 Sep 26.

21.

Characterising the effect of antimalarial drugs on the maturation and clearance of murine blood-stage Plasmodium parasites in vivo.

Khoury DS, Cromer D, Elliott T, Soon MSF, Thomas BS, James KR, Best SE, Aogo RA, Engel JA, Gartlan KH, Akter J, Sebina I, Haque A, Davenport MP.

Int J Parasitol. 2017 Dec;47(14):913-922. doi: 10.1016/j.ijpara.2017.05.009. Epub 2017 Aug 31.

PMID:
28864033
22.

Partial efficacy of a broadly neutralizing antibody against cell-associated SHIV infection.

Parsons MS, Lloyd SB, Lee WS, Kristensen AB, Amarasena T, Center RJ, Keele BF, Lifson JD, LaBranche CC, Montefiori D, Wines BD, Hogarth PM, Swiderek KM, Venturi V, Davenport MP, Kent SJ.

Sci Transl Med. 2017 Aug 9;9(402). pii: eaaf1483. doi: 10.1126/scitranslmed.aaf1483.

PMID:
28794282
23.

A mechanistic model quantifies artemisinin-induced parasite growth retardation in blood-stage Plasmodium falciparum infection.

Cao P, Klonis N, Zaloumis S, Khoury DS, Cromer D, Davenport MP, Tilley L, Simpson JA, McCaw JM.

J Theor Biol. 2017 Oct 7;430:117-127. doi: 10.1016/j.jtbi.2017.07.017. Epub 2017 Jul 18.

PMID:
28728995
24.

Fc functional antibodies in humans with severe H7N9 and seasonal influenza.

Vanderven HA, Liu L, Ana-Sosa-Batiz F, Nguyen TH, Wan Y, Wines B, Hogarth PM, Tilmanis D, Reynaldi A, Parsons MS, Hurt AC, Davenport MP, Kotsimbos T, Cheng AC, Kedzierska K, Zhang X, Xu J, Kent SJ.

JCI Insight. 2017 Jul 6;2(13). pii: 92750. doi: 10.1172/jci.insight.92750. eCollection 2017 Jul 6.

25.

Host-mediated impairment of parasite maturation during blood-stage Plasmodium infection.

Khoury DS, Cromer D, Akter J, Sebina I, Elliott T, Thomas BS, Soon MSF, James KR, Best SE, Haque A, Davenport MP.

Proc Natl Acad Sci U S A. 2017 Jul 18;114(29):7701-7706. doi: 10.1073/pnas.1618939114. Epub 2017 Jul 3.

26.

Anti-HIV-1 ADCC Antibodies following Latency Reversal and Treatment Interruption.

Lee WS, Kristensen AB, Rasmussen TA, Tolstrup M, Østergaard L, Søgaard OS, Wines BD, Hogarth PM, Reynaldi A, Davenport MP, Emery S, Amin J, Cooper DA, Kan VL, Fox J, Gruell H, Parsons MS, Kent SJ.

J Virol. 2017 Jul 12;91(15). pii: e00603-17. doi: 10.1128/JVI.00603-17. Print 2017 Aug 1.

27.

Genetically-barcoded SIV facilitates enumeration of rebound variants and estimation of reactivation rates in nonhuman primates following interruption of suppressive antiretroviral therapy.

Fennessey CM, Pinkevych M, Immonen TT, Reynaldi A, Venturi V, Nadella P, Reid C, Newman L, Lipkey L, Oswald K, Bosche WJ, Trivett MT, Ohlen C, Ott DE, Estes JD, Del Prete GQ, Lifson JD, Davenport MP, Keele BF.

PLoS Pathog. 2017 May 4;13(5):e1006359. doi: 10.1371/journal.ppat.1006359. eCollection 2017 May.

28.

Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents.

Petravic J, Rasmussen TA, Lewin SR, Kent SJ, Davenport MP.

J Virol. 2017 Apr 13;91(9). pii: e02092-16. doi: 10.1128/JVI.02092-16. Print 2017 May 1.

29.

Modeling the dynamics of neonatal CD8+ T-cell responses.

Reynaldi A, Smith NL, Schlub TE, Venturi V, Rudd BD, Davenport MP.

Immunol Cell Biol. 2016 Oct;94(9):838-848. doi: 10.1038/icb.2016.47. Epub 2016 May 4.

30.

Source of CpG Depletion in the HIV-1 Genome.

Alinejad-Rokny H, Anwar F, Waters SA, Davenport MP, Ebrahimi D.

Mol Biol Evol. 2016 Dec;33(12):3205-3212. Epub 2016 Sep 28.

PMID:
27682824
31.

Modeling of EBV Infection and Antibody Responses in Kenyan Infants With Different Levels of Malaria Exposure Shows Maternal Antibody Decay is a Major Determinant of Early EBV Infection.

Reynaldi A, Schlub TE, Piriou E, Ogolla S, Sumba OP, Moormann AM, Rochford R, Davenport MP.

J Infect Dis. 2016 Nov 1;214(9):1390-1398. Epub 2016 Aug 28.

32.

Correction: HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days-Implications for HIV Remission.

Pinkevych M, Cromer D, Tolstrup M, Grimm AJ, Cooper DA, Lewin SR, Søgaard OS, Rasmussen TA, Kent SJ, Kelleher AD, Davenport MP.

PLoS Pathog. 2016 Aug 25;12(8):e1005745. doi: 10.1371/journal.ppat.1005745. eCollection 2016 Aug.

33.

Modeling of Experimental Data Supports HIV Reactivation from Latency after Treatment Interruption on Average Once Every 5-8 Days.

Pinkevych M, Kent SJ, Tolstrup M, Lewin SR, Cooper DA, Søgaard OS, Rasmussen TA, Kelleher AD, Cromer D, Davenport MP.

PLoS Pathog. 2016 Aug 25;12(8):e1005740. doi: 10.1371/journal.ppat.1005740. eCollection 2016 Aug. No abstract available.

34.

Artemisinin-Based Treatments in Pregnant Women with Malaria.

Adekunle AI, Cromer D, Davenport MP.

N Engl J Med. 2016 Jul 21;375(3):283. doi: 10.1056/NEJMc1604709. No abstract available.

PMID:
27468068
35.

IL-15 promotes activation and expansion of CD8+ T cells in HIV-1 infection.

Younes SA, Freeman ML, Mudd JC, Shive CL, Reynaldi A, Panigrahi S, Estes JD, Deleage C, Lucero C, Anderson J, Schacker TW, Davenport MP, McCune JM, Hunt PW, Lee SA, Serrano-Villar S, Debernardo RL, Jacobson JM, Canaday DH, Sekaly RP, Rodriguez B, Sieg SF, Lederman MM.

J Clin Invest. 2016 Jul 1;126(7):2745-56. doi: 10.1172/JCI85996. Epub 2016 Jun 20.

36.

Defining the Effectiveness of Antimalarial Chemotherapy: Investigation of the Lag in Parasite Clearance Following Drug Administration.

Khoury DS, Cromer D, Möhrle JJ, McCarthy JS, Davenport MP.

J Infect Dis. 2016 Sep 1;214(5):753-61. doi: 10.1093/infdis/jiw234. Epub 2016 May 31.

37.

Analysis of the In Vivo Turnover of CD4+ T-Cell Subsets in Chronically SIV-Infected Sooty Mangabeys.

Ortiz AM, Carnathan DG, Yu J, Sheehan KM, Kim P, Reynaldi A, Vanderford TH, Klatt NR, Brenchley JM, Davenport MP, Silvestri G.

PLoS One. 2016 May 26;11(5):e0156352. doi: 10.1371/journal.pone.0156352. eCollection 2016.

38.

HIV-1 Mutation and Recombination Rates Are Different in Macrophages and T-cells.

Cromer D, Schlub TE, Smyth RP, Grimm AJ, Chopra A, Mallal S, Davenport MP, Mak J.

Viruses. 2016 Apr 22;8(4):118. doi: 10.3390/v8040118.

39.

High fidelity simian immunodeficiency virus reverse transcriptase mutants have impaired replication in vitro and in vivo.

Lloyd SB, Lichtfuss M, Amarasena TH, Alcantara S, De Rose R, Tachedjian G, Alinejad-Rokny H, Venturi V, Davenport MP, Winnall WR, Kent SJ.

Virology. 2016 May;492:1-10. doi: 10.1016/j.virol.2016.02.008. Epub 2016 Feb 19.

40.

The Neonatal CD8+ T Cell Repertoire Rapidly Diversifies during Persistent Viral Infection.

Venturi V, Nzingha K, Amos TG, Charles WC, Dekhtiarenko I, Cicin-Sain L, Davenport MP, Rudd BD.

J Immunol. 2016 Feb 15;196(4):1604-16. doi: 10.4049/jimmunol.1501867. Epub 2016 Jan 13.

41.

Estimating the in-vivo HIV template switching and recombination rate.

Cromer D, Grimm AJ, Schlub TE, Mak J, Davenport MP.

AIDS. 2016 Jan;30(2):185-92. doi: 10.1097/QAD.0000000000000936.

PMID:
26691546
42.

Impact of Plasmodium falciparum Coinfection on Longitudinal Epstein-Barr Virus Kinetics in Kenyan Children.

Reynaldi A, Schlub TE, Chelimo K, Sumba PO, Piriou E, Ogolla S, Moormann AM, Rochford R, Davenport MP.

J Infect Dis. 2016 Mar 15;213(6):985-91. doi: 10.1093/infdis/jiv525. Epub 2015 Nov 3.

43.

Tentative first steps to eradicate latent HIV.

Kent SJ, Davenport MP.

Lancet HIV. 2014 Oct;1(1):e2-3. doi: 10.1016/S2352-3018(14)70015-3. Epub 2014 Sep 15. No abstract available.

PMID:
26423812
44.

HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days--Implications for HIV Remission.

Pinkevych M, Cromer D, Tolstrup M, Grimm AJ, Cooper DA, Lewin SR, Søgaard OS, Rasmussen TA, Kent SJ, Kelleher AD, Davenport MP.

PLoS Pathog. 2015 Jul 2;11(7):e1005000. doi: 10.1371/journal.ppat.1005000. eCollection 2015 Jul. Erratum in: PLoS Pathog. 2016 Aug;12(8):e1005745.

45.

Reduced erythrocyte susceptibility and increased host clearance of young parasites slows Plasmodium growth in a murine model of severe malaria.

Khoury DS, Cromer D, Best SE, James KR, Sebina I, Haque A, Davenport MP.

Sci Rep. 2015 May 6;5:9412. doi: 10.1038/srep09412.

46.

Epitope-specific CD8+ T cell kinetics rather than viral variability determine the timing of immune escape in simian immunodeficiency virus infection.

Martyushev AP, Petravic J, Grimm AJ, Alinejad-Rokny H, Gooneratne SL, Reece JC, Cromer D, Kent SJ, Davenport MP.

J Immunol. 2015 May 1;194(9):4112-21. doi: 10.4049/jimmunol.1400793. Epub 2015 Mar 30.

47.

Modeling the dynamics of Plasmodium vivax infection and hypnozoite reactivation in vivo.

Adekunle AI, Pinkevych M, McGready R, Luxemburger C, White LJ, Nosten F, Cromer D, Davenport MP.

PLoS Negl Trop Dis. 2015 Mar 17;9(3):e0003595. doi: 10.1371/journal.pntd.0003595. eCollection 2015 Mar.

48.

Time-to-infection by Plasmodium falciparum is largely determined by random factors.

Pinkevych M, Chelimo K, Vulule J, Kazura JW, Moormann AM, Davenport MP.

BMC Med. 2015 Jan 30;13:19. doi: 10.1186/s12916-014-0252-9.

49.

Innate immunity induced by Plasmodium liver infection inhibits malaria reinfections.

Liehl P, Meireles P, Albuquerque IS, Pinkevych M, Baptista F, Mota MM, Davenport MP, Prudêncio M.

Infect Immun. 2015 Mar;83(3):1172-80. doi: 10.1128/IAI.02796-14. Epub 2015 Jan 12.

50.

CD161 defines a transcriptional and functional phenotype across distinct human T cell lineages.

Fergusson JR, Smith KE, Fleming VM, Rajoriya N, Newell EW, Simmons R, Marchi E, Björkander S, Kang YH, Swadling L, Kurioka A, Sahgal N, Lockstone H, Baban D, Freeman GJ, Sverremark-Ekström E, Davis MM, Davenport MP, Venturi V, Ussher JE, Willberg CB, Klenerman P.

Cell Rep. 2014 Nov 6;9(3):1075-88. doi: 10.1016/j.celrep.2014.09.045. Epub 2014 Oct 23.

Supplemental Content

Loading ...
Support Center